MARKET

MESO

MESO

Mesoblast
NASDAQ
11.11
+0.09
+0.82%
After Hours: 11.50 +0.39 +3.51% 19:57 07/11 EDT
OPEN
11.00
PREV CLOSE
11.02
HIGH
11.22
LOW
10.81
VOLUME
242.49K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
5.78
MARKET CAP
1.42B
P/E (TTM)
-12.1620
1D
5D
1M
3M
1Y
5Y
1D
Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)
Seeking Alpha · 4d ago
Weekly Report: what happened at MESO last week (0630-0704)?
Weekly Report · 5d ago
Buy Rating for Mesoblast: FDA Alignment and Promising Revascor Data Drive Optimism
TipRanks · 07/03 19:55
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 07/02 12:22
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/02 09:55
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
Benzinga · 07/01 14:38
Mesoblast, FDA agree on marketing application for cell therapy
Seeking Alpha · 07/01 13:57
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor
Benzinga · 07/01 12:46
More
About MESO
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.